In this study, HLX22 in combination with HLX02 regulated various cellular processes regarding anti-proliferation, induction of apoptosis, inhibition of tumor migration and prevention of drug resistance through intervening the EGFR receptor family related protein signal transductions, as well as down-regulation of gene expressions involving FGF-FGFR-PI3K-MTOR, EGF-EGFR-RAS, TGF-β-SMAD, PLCG, and cell cycle progression related pathways, which ultimately orchestrated the synergistic antitumor efficacy. Here, EGFR is linked to neoplasm.